TIER方案治疗复发/难治性原发性中枢神经系统淋巴瘤的1/2期研究
该多中心1/2期研究评估了塞替派联合异环磷酰胺、依托泊苷和利妥昔单抗(TIER)方案治疗复发/难治性原发性中枢神经系统淋巴瘤(rrPCNSL)的疗效与安全性。1期确定塞替派推荐2期剂量为50 mg/m2,2期27例患者中总缓解率52%,中位无进展生存期3个月,总生存期5个月。TIER方案安全可耐受,后续自体干细胞移植可带来持久缓解。
要点
- TIER方案在rrPCNSL中总缓解率达52%,满足预设活性阈值。
- 最常见3-4级毒性为中性粒细胞减少(56%)和血小板减少(39%)。
- 6例患者成功完成ASCT巩固,其中4例获持久缓解。
核心结论
- TIER方案可安全实施且对rrPCNSL有活性,后续ASCT可提供持久缓解和长期生存。
- 多数患者预后仍差,亟需新型治疗策略。
研究设计与样本
- 多中心1/2期研究,采用3+3设计确定塞替派推荐2期剂量,2期单阶段队列评估2周期TIER方案活性。
- 2期共治疗27例对高剂量甲氨蝶呤为基础化疗复发或难治的PCNSL患者。
主要发现
- 1期未遇剂量限制性毒性,确定塞替派50 mg/m2可安全用于TIER方案。
- 2期确认总缓解14例(52%),达到预设临床相关活性阈值。
- 中位无进展生存期3个月(95%CI 2-6个月),中位总生存期5个月(95%CI 3-9个月)。
- 探索性分析提示未接受过塞替派治疗的患者获益更大。
- 6例患者成功完成ASCT巩固,其中4例在中位随访50个月后仍处持久缓解。
关键数值与推荐
- 塞替派推荐2期剂量为50 mg/m2。
- 总缓解率52%(14/27)达到预设阈值。
临床怎么用
- TIER方案可作为rrPCNSL的挽救治疗选择,尤其对未接受过塞替派者可能获益更多。
- 对适合患者,TIER后序贯ASCT巩固可能实现持久缓解和长期生存。
局限性
- 样本量小(2期27例),随访时间有限。
- 多数患者预后仍差,需新策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapsed or refractory primary central nervous system lymphoma (rrPCNSL) confers a poor prognosis with no accepted standard of care. Very few prospective studies have been conducted in this patient group. This study was a multicenter phase 1/2 study that investigated thiotepa in combination with ifosfamide, etoposide, and rituximab (TIER) for the treatment of PCNSL relapsed or refractory to high-dose methotrexate-based chemotherapy. A 3 + 3 design investigated the recommended phase 2 dose of thiotepa for a single-stage phase 2 cohort by assessing the activity of 2 cycles of TIER against rrPCNSL. The primary outcome was overall response rate. The dose-finding study demonstrated that 50 mg/m2 of thiotepa could be safely delivered within the TIER regimen. No dose-limiting toxicities were encountered in phase 1, and TIER was well-tolerated by the 27 patients treated in phase 2. The most common grade 3 to 4 toxicities were neutropenia (56% of patients) and thrombocytopenia (39%). An overall response was confirmed in 14 patients (52%), which met the prespecified threshold for clinically relevant activity. The median progression-free survival was 3 months (95% confidence interval [CI], 2 to 6 months) and overall survival 5 months (95% CI, 3 to 9 months). Exploratory analyses suggest a greater benefit for thiotepa-naïve patients. Six patients successfully completed autologous stem cell transplantation (ASCT) consolidation, with 4 experiencing durable remissions after a median follow-up of 50 months. The TIER regimen can be delivered safely and is active against rrPCNSL. When it is followed by ASCT, it can provide durable remission and long-term survival. However, for the majority of patients, prognosis remains poor, and novel treatment strategies are urgently needed. This trial was registered at https://www.clinicaltrialsregister.eu/ctr-search/search as EudraCT 2014-000227-24 and ISRCTN 12857473.
引用
- Fox CP, Ali AS, McIlroy G, et al. A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial. Blood Adv. 2021. PMID: 34464973. doi:10.1182/bloodadvances.2021004779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。